Loading data for IRD — first visit, this takes a few seconds.
Opus Genetics, Inc. (IRD)
NasdaqCM: IRD
· 即時價格 · USD
3.60
-0.09 (-2.44%)
收盤價： Aug 31, 2026, 3:33 PM
股價、關鍵數字和最新消息，都在這一頁。
Opus Genetics, Inc.（IRD）股價、分析與資料
無可用資料
| 買價 | 2.78 |
| 市值 | 299M |
| 營收 (ttm) | 9.86M |
| 淨利（ttm） | -108M |
| 0.58 | |
| -1.29 | |
| n/a | |
| -5 | |
| P/B (ttm) | -22.92 |
| P/S (ttm) | 30.38 |
| 財報日期 | Nov 11, 2026 |
| 賣價 | 4.68 |
| 成交量 | 202,854 |
| 20 日平均成交量 | 967,107 |
| 開盤價 | 3.71 |
| 前收盤價 | 3.69 |
| 當日區間 | 3.56 - 3.72 |
| 52 週範圍 | 1.22 - 5.81 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 IRD
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The compa...
完整的公司簡介財報驚奇
Opus Genetics 已於 Aug 6, 2026 公布季度財報：
- 營收為 $755K 低於預期 $0, 年增 -73.80% 下滑.
- 每股盈餘為 -0.08 超出預期 0.08, 年增 33.33% 成長.
第 1 頁，共 2 頁